Simplified Chinese
Minhai Biotechnology was invited to attend the inaugural China Pharmaceutical Valley Future Biologics Innovative Drug Conference.
Release date:
2024-11-18
Author:
Source:
Abstract
11 16th of the month On [date], the inaugural China Pharmaceutical Valley – Future Biologics Innovative Drug Conference was successfully held at the Kapok Hotel in Daxing District. Hosted by the Management Committee of the Daxing Biopharmaceutical Industry Base of Zhongguancun Science Park and co-organized by six entities, including Beijing Hotgen Biotechnology Co., Ltd. and Beijing Minhai Biotechnology Co., Ltd., the event brought together numerous academicians, industry experts, and leading entrepreneurs to discuss cutting-edge industry trends, foster the deep integration of key drivers for the pharmaceutical and healthcare sectors, and further enhance Daxing District’s influence in the field of innovative drugs.
Zheng Haifa, Chief Scientist of Kangtai Biological and General Manager of Minhai Biological, was invited to attend the conference, where he delivered a live presentation titled “Trends in the Development of Next-Generation Vaccines,” and Together with other corporate representatives The unveiling ceremony marking the establishment of the “China Pharmaceutical Valley Biopharmaceutical Industry Alliance” was held.

In his on-site presentation, General Manager Zheng provided a clear and accessible overview of the background knowledge surrounding vaccines, offered a detailed analysis of emerging vaccine technology platforms, and outlined key trends and directions in the future development of vaccine technologies—such as multivalent and combination vaccines, viral vector vaccines, and novel adjuvants—eliciting an enthusiastic response from the audience.
At the event, President Zheng stated that China’s biopharmaceutical industry today faces both opportunities and challenges, and called on all sectors to provide greater support for the innovative development of biopharmaceutical companies. He expressed hope that, taking the convening of this conference and the establishment of the “China Pharmaceutical Valley Biopharmaceutical Industry Alliance” as a catalyst, more high‑quality enterprises would be brought together to jointly elevate China’s pharmaceutical R&D capabilities and help more outstanding domestically developed innovative drugs gain international recognition.
Looking ahead, Minhai Biologics will continue to serve as a leader in technological innovation within the biopharmaceutical industry. Leveraging the Daxing District Biopharmaceutical Industry Base and the high‑quality platform of the China Pharmaceutical Valley Biopharmaceutical Industry Alliance, the company will further strengthen cluster‑effect advantages and make even greater contributions to advancing the overall high‑quality development of China’s pharmaceutical and healthcare sectors.

Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09